Figure 3.

Risk strata distribution using REVEAL Lite 2 by medication cohort. (a) A higher proportion of patients with PAH who were initiated on PAH‐specific therapy were considered high risk, as compared to those initiated on prostacyclin (64% vs. 50%). (b, c) Of the patients deemed high risk by REVEAL Lite 2 who were in the “prostacyclin‐enriched” cohort not on parenteral prostacyclin therapy at baseline, 38% of patients initiated a parenteral prostacyclin within 90 days, as compared to 18% in the “any PAH medication” cohort. Numbers may not add to 100% due to rounding. PAH, pulmonary arterial hypertension; PCY, prostacyclin.